Wednesday, October 29, 2025

BeOne Medicines strengthens its German presence: Walter Gerhard Hafian-Hatzenbichler assumes the role of Director of Corporate Affairs Germany on a permanent basis

BeOne Medicines Germany GmbH has officially appointed Walter Gerhard Hafian-Hatzenbichler as Director of Corporate Affairs Germany. After serving in this position on an interim basis since June 2025, he will now take on the role permanently. In his new capacity, Hafian-Hatzenbichler will be responsible for BeOne Medicines’ strategic communications, political relations, and patient engagement activities in Germany.

BeOne Medicines is a leading global oncology company dedicated to making innovative cancer treatments more accessible to patients around the world.

With over a decade of experience in Corporate Affairs, Market Access, and Public Policy, Walter Gerhard Hafian-Hatzenbichler (41) has been a key figure within BeOne since joining in 2022 as Director of Market Access & Corporate Affairs Austria. He played a crucial role in the successful launch of several products in Austria and helped strengthen the company’s visibility and reputation through strategic initiatives.

“The appointment of Walter Hafian-Hatzenbichler is an important step in enhancing BeOne’s visibility and perception in Germany,” said Martin Völkl, General Manager Germany and Austria at BeOne Medicines. “His innovative mindset and collaborative approach make him a strong ambassador for our company culture and values.”

Hafian-Hatzenbichler added: “I am truly delighted to take on this role on a permanent basis. The past months have demonstrated how much potential lies in close collaboration with policymakers, patient organizations, and internal teams. Together with my colleagues, I aim to further strengthen BeOne Medicines’ position and foster access to innovative cancer therapies.”

Before joining BeOne Medicines, Hafian-Hatzenbichler – who studied European Studies and Political Economy at the University of Vienna – held positions at MSD and Celgene.

From BeiGene to BeOne Medicines

Formerly operating under the name BeiGene until June 2025, BeOne embodies a new era of global collaboration in cancer research. The new name reflects the company’s bold vision to defeat cancer through the transformative power of global cooperation and cross-sector partnerships.